Abstract: The present invention is a method for assigning a qualitative importance of relevant genetic phenotypes to the use of specific drugs for individual patients based on genetic test results. The invention provides a drug-centric integration of pharmacogenetic test information across multiple genes relevant to an individual drug. The invention then assigns a color designation for each drug reported and groups the drugs together on a report according to drug class/therapeutic area, thus allowing the physician to easily and quickly identify a drug from a specific drug class that would be best for that patient according to their entire pharmacogenetic test results. The outputs of the method can be added to existing pharmacogenetic test reports as a quick guide for the physician. Such integration of pharmacogenetic information from multiple genes and drug-centric organization of the outputs should allow physicians to more easily utilize and incorporate pharmacogenetic testing into their practice.